Friday, January 4, 2019

AmpliPhi Biosciences, C3J Therapeutics In Merger Deal

San Diego-based AmpliPhi Biosciences and Los Angeles-based C3J Therapeutics said this morning that the two have agreed to merge, in an all-stock deal, to focus on precisely targeted bacteriophage therapeutics. As part of the deal, the companies said C3J's existing shareholders will invest $10M in the merged company. AmpliPhi Biosciences is currently listed on the NYSE American as APH

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.

---